ANI Pharmaceuticals (NASDAQ: ANIP) and Intrexon (NYSE:XON) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.


This table compares ANI Pharmaceuticals and Intrexon’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ANI Pharmaceuticals 4.45% 22.40% 11.14%
Intrexon -66.88% -18.68% -11.34%

Volatility and Risk

ANI Pharmaceuticals has a beta of 2.9, indicating that its share price is 190% more volatile than the S&P 500. Comparatively, Intrexon has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.

Insider and Institutional Ownership

55.1% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 77.5% of Intrexon shares are held by institutional investors. 31.8% of ANI Pharmaceuticals shares are held by insiders. Comparatively, 56.3% of Intrexon shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares ANI Pharmaceuticals and Intrexon’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ANI Pharmaceuticals $128.62 million 6.44 $3.93 million $0.63 112.79
Intrexon $190.93 million 9.36 -$186.61 million ($1.12) -13.21

ANI Pharmaceuticals has higher earnings, but lower revenue than Intrexon. Intrexon is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for ANI Pharmaceuticals and Intrexon, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ANI Pharmaceuticals 0 1 2 0 2.67
Intrexon 0 1 5 0 2.83

ANI Pharmaceuticals presently has a consensus price target of $71.00, indicating a potential downside of 0.08%. Intrexon has a consensus price target of $38.50, indicating a potential upside of 160.14%. Given Intrexon’s stronger consensus rating and higher probable upside, analysts plainly believe Intrexon is more favorable than ANI Pharmaceuticals.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.

Intrexon Company Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with's FREE daily email newsletter.